Plain-language summary
Umbilical cord mesenchymal stromal cells are among the most widely used cell products in regenerative medicine: they are easy to obtain, can be expanded at scale, and have broad immunomodulatory effects. Their track record after intravenous infusion, however, is complicated by a delivery problem — most cells become trapped in the fine vessels of the lungs on the first pass, and few reach their intended targets. This review assembles what is known about how these cells move through the body. It argues that the classic white-blood-cell adhesion model only partly explains cultured stromal cells, whose chemokine receptors and adhesion molecules vary widely between donors and culture conditions. It also highlights often-overlooked factors: inflammatory reactions in the blood, complement and coagulation activation, and loss of function after freezing and thawing. Notably, therapeutic benefit often occurs even though very few cells persist, pointing to secreted factors and extracellular vesicles as the likely true effectors. The authors close with strategies to improve delivery, including preconditioning, route optimization and biomaterial-assisted retention.
Key findings
- Intravenously delivered umbilical cord MSCs are largely sequestered in the lungs on the first pass, which limits where the cells actually reach.
- The leukocyte adhesion model incompletely describes cultured UC-MSCs, whose chemokine receptors and adhesion molecules are heterogeneous across donors and culture conditions.
- Therapeutic benefit often occurs despite minimal durable engraftment, implicating paracrine signaling and extracellular vesicles as key effectors.
- Optimization strategies include preconditioning, glycoengineering, route selection, biomaterial-assisted retention and GMP-grade potency assays.
Why this matters for lung repair
This review is about cell therapy logistics rather than a single disease, but it is unusually relevant to vesicle-based approaches: it explicitly names extracellular vesicles as likely mediators of MSC benefit and explains why the delivery route — including avoiding pulmonary first-pass sequestration — determines biodistribution, a central question for any inhaled vesicle therapy.
Original abstract
Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) offer distinct advantages for clinical translation, including accessibility, scalability, and broad immunomodulatory capacity. However, the efficacy of systemically delivered UC-MSCs is constrained by suboptimal in vivo trafficking. Intravascular administration is limited by pulmonary first-pass sequestration, inefficient endothelial recruitment, blood-mediated inflammatory injury, and poor retention. While UC-MSCs homing is often conceptualized through a leukocyte adhesion paradigm, this model incompletely describes culture-expanded UC-MSCs, which exhibit heterogeneous expression of chemokine receptors, adhesion molecules, and selectin ligands. Furthermore, biodistribution and safety are critically determined by biophysical and hemocompatibility parameters, including cell size, deformability, cryopreservation status, and tissue factor (TF/CD142)-dependent procoagulant activity. This review synthesizes current understanding of UC-MSCs trafficking at the translational interface of biology and manufacturing. We examine canonical migratory mechanisms-chemokine signaling, integrin-mediated adhesion, extracellular matrix remodeling, and intracellular motility pathways-alongside underappreciated determinants of therapeutic performance: instant blood-mediated inflammatory reaction (IBMIR), complement-coagulation crosstalk, post-thaw functional impairment, donor variability, and route-dependent biodistribution. We also address the paradox wherein therapeutic benefit occurs despite minimal durable engraftment, implicating paracrine signaling, extracellular vesicles, and apoptosis-associated immune reprogramming as primary effectors. Finally, we evaluate strategies to enhance delivery and efficacy, including preconditioning, glycoengineering, receptor overexpression, route optimization, biomaterial-assisted retention, and migration-relevant potency assays under Good Manufacturing Practice (GMP). Advancing UC-MSCs therapy toward reproducible, mechanism-guided clinical application requires rigorous integration of hemocompatibility assessment, product characterization, and clinically informative cell tracking.
Frequently asked questions
What did this study find?
Umbilical cord mesenchymal stromal cells are among the most widely used cell products in regenerative medicine: they are easy to obtain, can be expanded at scale, and have broad immunomodulatory effects. Their track record after intravenous infusion, however, is complicated by a delivery problem — most cells become trapped in the fine vessels of the lungs on the first pass, and few reach their intended targets. This review assembles what is known about how these cells move through the body. It argues that the classic white-blood-cell adhesion model only partly explains cultured stromal cells, whose chemokine receptors and adhesion molecules vary widely between donors and culture conditions. It also highlights often-overlooked factors: inflammatory reactions in the blood, complement and coagulation activation, and loss of function after freezing and thawing. Notably, therapeutic benefit often occurs even though very few cells persist, pointing to secreted factors and extracellular vesicles as the likely true effectors. The authors close with strategies to improve delivery, including preconditioning, route optimization and biomaterial-assisted retention.
Was this tested in humans or in the laboratory?
This is a review: it summarises and weighs up previously published studies rather than presenting new experiments.
Where can I read the original paper?
The full text lives with the publisher: https://doi.org/10.1007/s12015-026-11210-9
Does this study prove that JuvGuard works?
No. This is an independent, peer-reviewed study on extracellular vesicles. JuvGuard references the published literature for education only. A single paper cannot establish that any product works, and nothing here is medical advice.
How to cite this paper
Liu XueXia, Liu FuJun. Homing and Migration of Umbilical Cord Mesenchymal Stromal Cells in Clinical Applications: Molecular Mechanisms, Translational Barriers, and Therapeutic Optimization.. Stem cell reviews and reports. 2026, 2026-08-07. DOI: 10.1007/s12015-026-11210-9
Source & verification
- Journal: Stem cell reviews and reports
- Published: 7 August 2026
- DOI: 10.1007/s12015-026-11210-9
- PubMed ID: 42566160
- Indexed via: pubmed
- MeSH terms: Humans, Mesenchymal Stem Cells, Umbilical Cord, Cell Movement, Mesenchymal Stem Cell Transplantation, Animals, Translational Research, Biomedical